RareCan Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC
  • (Upcoming)

  • Investors
  • 8

RareCan General Information

Description

Developer of a direct-to-patient clinical trial platform designed to improve outcomes for cancer patients. The company's platform develops novel patient and data pipelines, underpinned by proprietary technology, that make it quicker and cheaper for the global pharmaceutical industry to access the patients and data needed to deliver precision medicine trials and accelerate the pace at which new precision medicines are brought to market, enabling researchers to find treatments for cancer and increase the success rate of rare cancer trials for the global cancer drug market.

Contact Information

Website
www.rarecan.com
Formerly Known As
Moramora
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8 Park Avenue
  • Hexham NE46 3EN
  • England, United Kingdom
+44 07500
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Healthcare Technology Systems
Other Healthcare Services
Corporate Office
  • 8 Park Avenue
  • Hexham NE46 3EN
  • England, United Kingdom
+44 07500

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RareCan Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC Upcoming Generating Revenue
6. Accelerator/Incubator 01-Dec-2024 Completed Generating Revenue
5. Grant Completed Generating Revenue
4. Accelerator/Incubator 08-Nov-2022 Completed Generating Revenue
3. Seed Round 28-Jun-2022 Completed Generating Revenue
2. Seed Round 19-Mar-2021 $279K $279K Completed Generating Revenue
1. Grant 01-Jan-2021 $2.68K Completed Generating Revenue
To view RareCan’s complete valuation and funding history, request access »

RareCan Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view RareCan’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

RareCan Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RareCan Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioIndustry Association Accelerator/Incubator
The Francis Crick Institute Accelerator/Incubator Minority
Anglia Angels Angel Group Minority
Cambridge Angels Angel Group Minority
Women Angels Angel Group Minority
You’re viewing 5 of 8 investors. Get the full list »

RareCan FAQs

  • When was RareCan founded?

    RareCan was founded in 2019.

  • Where is RareCan headquartered?

    RareCan is headquartered in Hexham, United Kingdom.

  • What is the size of RareCan?

    RareCan has 6 total employees.

  • What industry is RareCan in?

    RareCan’s primary industry is Discovery Tools (Healthcare).

  • Is RareCan a private or public company?

    RareCan is a Private company.

  • What is RareCan’s current revenue?

    The current revenue for RareCan is .

  • How much funding has RareCan raised over time?

    RareCan has raised $926K.

  • Who are RareCan’s investors?

    BioIndustry Association, The Francis Crick Institute, Anglia Angels, Cambridge Angels, and Women Angels are 5 of 8 investors who have invested in RareCan.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process